Kleczko EK[au] - Search Results

Year	Number of Results
2014	1
2015	3
2018	2
2019	5
2020	2
2021	1
2022	2

1

Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.

Gadwa J, Bickett TE, Darragh LB, Knitz MW, Bhatia S, Piper M, Van Court B, Bhuvane S, Nguyen D, Nangia V, Kleczko EK, Nemenoff RA, Karam SD. Gadwa J, et al. Among authors: kleczko ek. J Immunother Cancer. 2021 Mar;9(3):e002585. doi: 10.1136/jitc-2021-002585. J Immunother Cancer. 2021. PMID: 33789881 Free PMC article.

2

Eicosanoids in Cancer: New Roles in Immunoregulation.

Johnson AM, Kleczko EK, Nemenoff RA. Johnson AM, et al. Among authors: kleczko ek. Front Pharmacol. 2020 Nov 18;11:595498. doi: 10.3389/fphar.2020.595498. eCollection 2020. Front Pharmacol. 2020. PMID: 33364964 Free PMC article. Review.

3

Renal double negative T cells: unconventional cells in search of a function.

Nemenoff RA, Kleczko EK, Hopp K. Nemenoff RA, et al. Among authors: kleczko ek. Ann Transl Med. 2019 Dec;7(Suppl 8):S342. doi: 10.21037/atm.2019.09.107. Ann Transl Med. 2019. PMID: 32016060 Free PMC article. No abstract available.

4

Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer.

Kleczko EK, Kwak JW, Schenk EL, Nemenoff RA. Kleczko EK, et al. Front Immunol. 2019 May 10;10:954. doi: 10.3389/fimmu.2019.00954. eCollection 2019. Front Immunol. 2019. PMID: 31134065 Free PMC article. Review.

5

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.

Kleczko EK, Heasley LE. Kleczko EK, et al. Mol Cancer. 2018 Feb 19;17(1):60. doi: 10.1186/s12943-018-0816-y. Mol Cancer. 2018. PMID: 29458371 Free PMC article. Review.

6

CD8⁺ T cells modulate autosomal dominant polycystic kidney disease progression.

Kleczko EK, Marsh KH, Tyler LC, Furgeson SB, Bullock BL, Altmann CJ, Miyazaki M, Gitomer BY, Harris PC, Weiser-Evans MCM, Chonchol MB, Clambey ET, Nemenoff RA, Hopp K. Kleczko EK, et al. Kidney Int. 2018 Dec;94(6):1127-1140. doi: 10.1016/j.kint.2018.06.025. Epub 2018 Sep 21. Kidney Int. 2018. PMID: 30249452 Free PMC article.

7

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti-PD-1 response in NSCLC.

Bullock BL, Kimball AK, Poczobutt JM, Neuwelt AJ, Li HY, Johnson AM, Kwak JW, Kleczko EK, Kaspar RE, Wagner EK, Hopp K, Schenk EL, Weiser-Evans MC, Clambey ET, Nemenoff RA. Bullock BL, et al. Among authors: kleczko ek. Life Sci Alliance. 2019 May 27;2(3):e201900328. doi: 10.26508/lsa.201900328. Print 2019 Jun. Life Sci Alliance. 2019. PMID: 31133614 Free PMC article.

8

Metabolic reprogramming in a slowly developing orthologous model of polycystic kidney disease.

Hopp K, Kleczko EK, Gitomer BY, Chonchol M, Klawitter J, Christians U, Klawitter J. Hopp K, et al. Among authors: kleczko ek. Am J Physiol Renal Physiol. 2022 Mar 1;322(3):F258-F267. doi: 10.1152/ajprenal.00262.2021. Epub 2022 Jan 17. Am J Physiol Renal Physiol. 2022. PMID: 35037466

9

Functional RNAi Screens Define Distinct Protein Kinase Vulnerabilities in EGFR-Dependent HNSCC Cell Lines.

Hinz TK, Kleczko EK, Singleton KR, Calhoun J, Marek LA, Kim J, Tan AC, Heasley LE. Hinz TK, et al. Among authors: kleczko ek. Mol Pharmacol. 2019 Dec;96(6):862-870. doi: 10.1124/mol.119.117804. Epub 2019 Sep 25. Mol Pharmacol. 2019. PMID: 31554698 Free PMC article.

10

Activation of PPARγ in Myeloid Cells Promotes Progression of Epithelial Lung Tumors through TGFβ1.

Sippel TR, Johnson AM, Li HY, Hanson D, Nguyen TT, Bullock BL, Poczobutt JM, Kwak JW, Kleczko EK, Weiser-Evans MC, Nemenoff RA. Sippel TR, et al. Among authors: kleczko ek. Mol Cancer Res. 2019 Aug;17(8):1748-1758. doi: 10.1158/1541-7786.MCR-19-0236. Epub 2019 May 14. Mol Cancer Res. 2019. PMID: 31088909 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results